Crinecerfont

US FDA approved crinecerfont (Crenessity) for congenital adrenal hyperplasia (CAH) in adults and children aged 4+; first new therapy for CAH in 70 years. Indicated as adjunctive treatment to glucocorticoid replacement therapy, it reduces excess adrenal androgens. Based on phase 3 CAHtalyst trial data.

FDA approves crinecerfont (Crenessity) for classic congenital adrenal hyperplasia (CAH), a rare genetic condition affecting adrenal glands. It reduces adrenal androgen overproduction, allowing lower glucocorticoid doses. Trials showed significant reductions in androstenedione levels and glucocorticoid doses in both adults and children. Common side effects include tiredness, dizziness, and muscle pain. Available in capsules and oral solution via PANTHERx Rare.

Crinecerfont (Crenessity) received FDA approval for classic congenital adrenal hyperplasia (CAH), the first new treatment in 70 years. It reduces adrenal androgen production, allowing lower glucocorticoid doses, with demonstrated efficacy and safety in pediatric and adult studies.

Patient Care's year-end video series features interviews with physician scientists discussing important clinical trials, implications for primary care, and novel additions to patient care. Richard Auchus, MD, PhD, focuses on congenital adrenal hyperplasia, its impact, standard care challenges, and the promise of newly approved CRF1 antagonist crinecerfont.

Neurocrine Biosciences' Crenessity (crinecerfont) receives FDA approval, marking the first new CAH treatment in 70 years. This oral therapy addresses a treatment gap for CAH, a life-threatening endocrine disorder affecting 30,000 in the U.S. Crenessity reduces glucocorticoid dosage, controlling ACTH overproduction and offering a safer alternative to steroid treatments.

FDA approves Neurocrine's Crenessity for classic congenital adrenal hyperplasia, marking the first targeted treatment. Crenessity reduces excess adrenocorticotropic hormone and adrenal androgen production, allowing glucocorticoid dose reduction. Analysts see blockbuster potential, emphasizing patient and clinician education for market success.

The FDA approved crinecerfont (Crenessity) as the first-in-class treatment for classic congenital adrenal hyperplasia (CAH) in patients 4 years and older. It reduces excessive adrenal androgen production, allowing for lower glucocorticoid doses. Two trials supported its approval, showing significant reductions in androstenedione levels and glucocorticoid doses. Common side effects include fatigue, dizziness, and arthralgia. It will be available in 50-mg and 100-mg capsules and a 50-mg/mL oral solution through PANTHERx Rare.

FDA approves Neurocrine’s Crenessity for CAH, an adjunct treatment to glucocorticoid replacement for controlling androgens in adults and children ages four and older. The approval is supported by the CAHtalyst clinical program, showing significant reductions in androstenedione and steroid doses. Crenessity is expected to be commercially available shortly.

Richard Auchus, MD, PhD, details the CAHtalyst phase 3 clinical trial of crinecerfont, leading to FDA approval for treating classic CAH in adults and children by blocking ACTH release and adrenal androgen overproduction.

FDA approves Crenessity (crinecerfont) for classic congenital adrenal hyperplasia (CAH), reducing excess ACTH and adrenal androgen production, enabling glucocorticoid dose reduction. Available through PANTHERx Rare, with Neurocrine Access Support for patient assistance.